Actuate Therapeutics Inc (ACTU) annual income statement — 4-year revenue, gross profit & net income history
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 |
| Revenue Growth % | - | - | - | - | - |
| Cost of Goods Sold | 0 | 0 | 0 | 0 | 0 |
| COGS % of Revenue | - | - | - | - | - |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Gross Margin % | - | - | - | - | - |
| Gross Profit Growth % | - | - | - | - | - |
| Operating Expenses | 21.83M | 22.5M | 25.16M | 24.97M | 20.21M |
| OpEx % of Revenue | - | - | - | - | - |
| Selling, General & Admin | 12.2M | 12.2M | 6.48M | 3.27M | 3.82M |
| SG&A % of Revenue | - | - | - | - | - |
| Research & Development | 9.64M | 10.29M | 18.68M | 21.71M | 16.39M |
| R&D % of Revenue | - | - | - | - | - |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -21.83M | -22.5M | -25.16M | -24.97M | -20.21M |
| Operating Margin % | - | - | - | - | - |
| Operating Income Growth % | - | 10.59% | -0.75% | -23.59% | - |
| EBITDA | -21.74M | -22.5M | -23.02M | -24.7M | -20.14M |
| EBITDA Margin % | - | - | - | - | - |
| EBITDA Growth % | 14.03% | 2.27% | 6.82% | -22.63% | - |
| D&A (Non-Cash Add-back) | 0 | 0 | 2.14M | 272.85K | 63.61K |
| EBIT | -21.74M | -22.49M | -27.3M | -24.7M | -20.14M |
| Net Interest Income | 299.11K | 267.46K | 241.01K | 309.03K | 10.83K |
| Interest Income | 319.36K | 287.71K | 222.29K | 352.67K | 27.03K |
| Interest Expense | 20.25K | 20.25K | -18.72K | 43.64K | 16.2K |
| Other Income/Expense | 299.11K | 267.46K | -2.12M | 229.21K | 47.41K |
| Pretax Income | -21.54M | -22.23M | -27.28M | -24.74M | -20.16M |
| Pretax Margin % | - | - | - | - | - |
| Income Tax | 800 | 0 | 800 | 0 | 0 |
| Effective Tax Rate % | -0% | 0% | -0% | 0% | 0% |
| Net Income | -21.54M | -22.23M | -27.29M | -24.74M | -20.16M |
| Net Margin % | - | - | - | - | - |
| Net Income Growth % | 14.9% | 18.54% | -10.27% | -22.74% | - |
| Net Income (Continuing) | -21.54M | -22.23M | -27.29M | -24.74M | -20.16M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.92 | -1.06 | -3.26 | -1.65 | -1.34 |
| EPS Growth % | 45.3% | 67.48% | -97.58% | -23.13% | - |
| EPS (Basic) | - | -1.06 | -3.26 | -1.65 | -1.34 |
| Diluted Shares Outstanding | 23.54M | 21.02M | 19.51M | 15.03M | 15.03M |
| Basic Shares Outstanding | 23.54M | 21.02M | 19.51M | 15.03M | 15.03M |
| Dividend Payout Ratio | - | - | - | - | - |
Quick answers to the most common questions about buying ACTU stock.
For fiscal year 2025, Actuate Therapeutics Inc (ACTU) reported total revenue of $0.0M.
Actuate Therapeutics Inc (ACTU) reported a net loss of $22.2M for the fiscal year ending 2025.